Get the Stockscreener App
0.84
5.00%
0.04
Cyclo Therapeutics Inc stock is traded at $0.84, with a volume of 90,498.
It is up +5.00% in the last 24 hours and up +33.33% over the past month.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
See More
Previous Close:
$0.80
Open:
$0.78
24h Volume:
90,498
Relative Volume:
2.36
Market Cap:
$27.50M
Revenue:
$1.13M
Net Income/Loss:
$-20.74M
P/E Ratio:
-0.9545
EPS:
-0.88
Net Cash Flow:
$-18.37M
1W Performance:
+23.53%
1M Performance:
+33.33%
6M Performance:
-30.58%
1Y Performance:
-48.15%
1-Day Range:
$0.761
$0.86
1-Week Range:
$0.6634
$0.86
52-Week Range:
$0.55
$2.115
Cyclo Therapeutics Inc Stock (CYTH) Company Profile
Name
Cyclo Therapeutics Inc
Sector
Phone
386-418-8060
Address
6714 NW 16TH STREET, SUITE B, GAINESVILLE
Compare CYTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTH
Cyclo Therapeutics Inc
|
0.84 | 27.50M | 1.13M | -20.74M | -18.37M | -0.88 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Cyclo Therapeutics Inc Stock (CYTH) Latest News
Cyclo Therapeutics Faces Potential Delisting Due to Failure to Hold Annual Shareholders MeetingUNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. – January 10, 2025 – ON January 10, 2025, Cyclo Therapeutics, Inc. (the “C - Defense World
Rafael Holdings reports favorable shareholder votes - Investing.com India
Cyclo Therapeutics to Present Groundbreaking Trappsol® Cyclo™ Research at WORLDSymposium 2025 - StockTitan
Cyclo Therapeutics faces Nasdaq delisting over meeting lapse - Investing.com
Sypris Solutions, Inc (SYPR): Worth A Small Bite At $2.12 - Stocks Register
AMRN Stock Rises Over 5% Amidst Lack of Institutional Ratings - GuruFocus.com
Cyclo Therapeutics, Inc. announced that it has received $1 million in funding - Marketscreener.com
Cyclo Therapeutics Enters into Significant Note Purchase Agreement with Rafael Holdings - Defense World
Cyclo Therapeutics inks $3M convertible note with Rafael Holdings By Investing.com - Investing.com Nigeria
Cyclo Therapeutics inks $3M convertible note with Rafael Holdings - Investing.com
CYTH stock touches 52-week low at $0.57 amid market challenges - Investing.com Australia
CYTH stock touches 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa
Critical Comparison: Curis (NASDAQ:CRIS) vs. Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Rafael Holdings Reports Conversion of Convertible Promissory Note into Cyclo Therapeutics Common Stock - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, SASR, AUB, CYTH on Behalf of Shareholders - The Eastern Progress Online
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, NURO, PWOD, CARA on Behalf of Shareholders - The Eastern Progress Online
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders - Benzinga
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate MergerZUO, CYTH, PDCO, SKGR - The Eastern Progress Online
Niemann-Pick Disease Type C Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Zevra Therapeutics, Azafaros A.G, IntraBio, Cyclo Therapeutics, Azafaros A.G - Barchart
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
Kuehn Law Encourages USAP, CYTH, ARCH, and FLIC Investors to Contact Law Firm - EIN News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARCH, CYTH on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc.CYTH - The Eastern Progress Online
$HAREHOLDER ALERT: The M&A Class Action Continues To Investigate MergerAE, ZUO, CYTH, EMKR - The Eastern Progress Online
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARCH, CYTH, VGR on Behalf of Shareholders - The Eastern Progress Online
CYTH Stock Plummets to 52-Week Low of $0.59 Amid Market Challenges - Investing.com Canada
CYTH Stock Plummets to 52-Week Low of $0.59 Amid Market Challenges By Investing.com - Investing.com South Africa
Rafael Holdings: Strategic Developments and Financial Insights - TipRanks
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results - The Manila Times
Rafael Holdings Reports Widening Losses Ahead of Strategic Cyclo Therapeutics Merger - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of CYTH, NAPA, MNTX and MARX - The Eastern Progress Online
Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm - The Eastern Progress Online
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - The Eastern Progress Online
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CYTH, BRKH, PIRS, CFB on Behalf of Shareholders - The Eastern Progress Online
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of CYTH, VBFC, CFB and MKFG - The Eastern Progress Online
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of BFAC, BCOV, CYTH and ARCH - The Eastern Progress Online
Cyclo Therapeutics Inc Stock (CYTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):